Particle.news

Download on the App Store

Serena Williams Discloses GLP-1 Use, Reports 31-Pound Loss, Joins Ro Campaign

Her announcement coincides with a Ro ambassador role that spotlights telehealth’s growing role in access to weight‑loss drugs.

Image
Image
Image
Image

Overview

  • Williams says she began GLP‑1 treatment after her second pregnancy, starting weekly injections in early 2024 once she stopped breastfeeding.
  • She reports improved health markers, including better blood sugar readings, less knee pain, more energy, and no personal side effects.
  • The tennis star is partnering with telehealth provider Ro to counter stigma around medical weight‑loss treatments.
  • Her husband, Alexis Ohanian, is an investor in Ro and sits on the company’s board, a relationship outlets noted in coverage of the partnership.
  • Some reports say she named the medication as Zepbound, while others note she did not specify the exact product.